10 news items
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
TAK
17 Jun 24
.
"We are grateful to all the participants and their families, as well as investigators and clinical staff
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
TAK
14 Jun 24
is investigating olverembatinib in multiple clinical studies in several types of cancer. Olverembatinib has been granted orphan drug designation
Takeda Presents Phase 2b Results for Narcolepsy Treatment at SLEEP 2024
TAK
3 Jun 24
2024, the 38th annual meeting of the American Academy of Sleep Medicine and the Sleep Research Society. TAK-861 is an investigational oral orexin
Takeda's TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
TAK
3 Jun 24
is an investigational oral orexin receptor 2 (OX2R) agonist and, based on the results, has the potential to provide transformative efficacy in addressing the overall
Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
TAK
31 May 24
. rADAMTS13 is also being investigated in adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP), the acquired form of TTP, in an ongoing
5dgmgpx
ACIU
TAK
13 May 24
has the potential to delay or slow Alzheimer’s disease progression.
ACI-24.060 is being investigated in the ongoing
kqp6amorkg04x1r 0xo7j
ACIU
TAK
13 May 24
inhibiting plaque formation in the brain, ACI-24.060 has the potential to delay or slow Alzheimer's disease progression. ACI-24.060 is being investigated
js0hlj2inwoobgzmtmzz9jpo73adup6wd03bqa7r0m
ACIU
TAK
13 May 24
investigated in the ongoing ABATE randomized, double-blind, placebo-controlled Phase 1b/2 trial to assess the safety, tolerability, immunogenicity
mqubd8j3rhp4pao0b7
TAK
26 Apr 24
investigated fruquintinib plus best supportive care (BSC) versus placebo plus BSC in patients with previously treated mCRC. FRESCO-2 met all its primary
dz7s627omkshq0bgo9v5jvgzd4erm8q ymwgi2v
TAK
26 Apr 24
investigated fruquintinib plus best supportive care (BSC) versus placebo plus BSC in patients with previously treated mCRC. FRESCO-2 met all its primary
- Prev
- 1
- Next